Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 10—October 2011
CME ACTIVITY - Research

Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009

Jan W.M. van der LindenComments to Author , Eveline Snelders, Greetje A. Kampinga, Bart J.A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J.G. Melchers, Paul E. Verweij, and Kuijper

Author affiliations: Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (J.W.M. van der Linden, E. Snelders, W.J.G. Melchers, P.E. Verweij); Groningen University Medical Centre, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Centre, Rotterdam, the Netherlands (B.J.A. Rijnders); Utrecht University Medical Centre, Utrecht, the Netherlands (E. Mattsson); Vrije University Medical Centre, Amsterdam, the Netherlands (Y.J. Debets-Ossenkopp); Leiden University Medical Centre, Leiden, the Netherlands (E.J. Kuijper); Maastricht University Medical Centre, Maastricht, the Netherlands (F.H. van Tiel)

Main Article

Table 3

Underlying diseases of patients from whom azole-susceptible and -resistant Aspergillus fumigatus isolates were recovered, the Netherlands, 2007–2009

Underlying condition No. (%) patients with susceptible isolates, n = 1,129 No. (%) patients with resistant isolates, n = 63 p value*
Cystic fibrosis 365 (32.3) 17 (27.0) 0.38
Pulmonary disease, excluding cystic fibrosis 251 (22.2) 14 (22.2) 1.00
Hematologic/oncologic disease 125 (11.1) 13 (20.6) 0.02
Otorhinolaryngologic disease 63 (5.6) 3 (4.8) 0.78
Internal disease 85 (7.5) 8 (12.7) 0.14
Solid organ transplantation 26 (2.3) 2 (3.2) 0.66
Intensive care unit patient 31 (2.7) 2 (3.2) 0.84
Cardiac disease 9 (0.8) 1 (1.6) 0.50
Chronic granulomatous disease 5 (0.4) 0 0.60
Postoperative condition 23 (2.0) 1 (1.6) 0.81
Neurologic disease 2 (0.2) 0 0.74
Disease in children, not specified 4 (0.4) 0 0.64
Dermatologic disease 6 (0.5) 1 (1.6) 0.29
Other 91 (8.1) 1 (1.6)
Unknown 43 (3.8) 0

2 test.

2 test.

2 test.

Main Article

Page created: September 22, 2011
Page updated: September 22, 2011
Page reviewed: September 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external